Sigma-Aldrich Names Jai Nagarkatti as Chief Executive Officer
News Nov 09, 2005
The Sigma-Aldrich Corporation's Board of Directors has announced the appointment of Jai Nagarkatti, 58, (President and Chief Operating Officer) as President and Chief Executive Officer effective January 1, 2006.
He will succeed Chairman and Chief Executive Officer David Harvey, 66, who will continue to serve as Chairman of the Company's Board of Directors. Jai Nagarkatti was also elected as a member of the Board of Directors.
Speaking on behalf of the Board, David R. Harvey stated, “Jai Nagarkatti is a very seasoned and knowledgeable leader who has had a major impact on the success and growth of Sigma-Aldrich.”
“His experience and insight into our business will serve the Company well as we continue our focus on Life Science and High Technology.”
Jai Nagarkatti noted, “I am pleased by the vote of confidence that the Board of Directors and David Harvey have given me and I look forward to the challenge of accelerating the performance of Sigma-Aldrich and strengthening the Company's position as a worldwide leader in our research and fine chemical businesses.”
The 29-year Sigma-Aldrich career of Jai Nagarkatti has spanned R&D, production, operations and sales and marketing.
Since August 2004, he has been Chief Operating Officer and President. Previously he served as the President of the largest research division and the fine chemicals business.
Jai Nagarkatti, a U.S. citizen, was born in Hyderabad, India. He obtained his Master's degree in chemistry at Osmania University in Hyderabad and subsequently a Ph.D. in organic chemistry at Texas A&M University.
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
SCRaMbLE Speeds Up Yeast EvolutionNews
Scientists have created a new way of speeding up the genome evolution of baker’s yeast Saccharomyces cerevisiae. This is to develop a synthetic yeast strain that can be transformed on demand, making it industrial applications such as the mass production of advanced medicines to treat illnesses such as malaria and tuberculosis (TB).READ MORE
Artificial Cellular Compartments BuiltNews
How to install new capabilities in cells without interfering with their metabolic processes? A team from the Technical University of Munich (TUM) and the Helmholtz Zentrum München have altered mammalian cells in such a way that they formed artificial compartments in which sequestered reactions could take place, allowing the detection of cells deep in the tissue and also their manipulation with magnetic fields.READ MORE